Global Cord Blood's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Global Cord Blood (CO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Global Cord Blood vs Its Competitors
- TTM: Trailing 12-month revenue of 194M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+305.0% annualized vs trailing 12 months).
- Peer revenue share: Global Cord Blood accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CO Sales vs. its Competitors, Q4 2022
Global Cord Blood generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 10.8% for Global Cord Blood. Global Cord Blood's share of combined industry revenue moved from 0.17% to 0.16%, a loss of 0.01 percentage points.
Global Cord Blood's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Global Cord Blood Corp | Yes | Yes | Yes | No |
| Similar Growth & Profitability (8) | 100.00 % (7 of 7) | 87.50 % (7 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.